Nicholson WE, Printz RL, Shiota M. Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp. Am J Physiol Endocrinol Metab 308: E206 -E222, 2015. First published December 16, 2014; doi:10.1152 doi:10. /ajpendo.00406.2014stand the underlying pathology of metabolic diseases, such as diabetes, an accurate determination of whole body glucose flux needs to be made by a method that maintains key physiological features. One such feature is a positive differential in insulin concentration between the portal venous and systemic arterial circulation (P/S-IG). P/S-IG during the determination of the relative contribution of liver and extraliver tissues/organs to whole body glucose flux during an insulin clamp with either systemic (SID) or portal (PID) insulin delivery was examined with insulin infusion rates of 1, 2, and 5 mU·kg Ϫ1 ·min
under either euglycemic or hyperglycemic conditions in 6-h-fasted conscious normal rats. A P/S-IG was initially determined with endogenous insulin secretion to exist with a value of 2.07. During an insulin clamp, while inhibiting endogenous insulin secretion by somatostatin, P/S-IG remained at 2.2 with PID, whereas, P/S-IG disappeared completely with SID, which exhibited higher arterial and lower portal insulin levels compared with PID. Consequently, glucose disappearance rates and muscle glycogen synthetic rates were higher, but suppression of endogenous glucose production and liver glycogen synthetic rates were lower with SID compared with PID. When the insulin clamp was performed with SID at 2 and 5 mU·kg Ϫ1 ·min
Ϫ1
without managing endogenous insulin secretion under euglycemic but not hyperglycemic conditions, endogenous insulin secretion was completely suppressed with SID, and the P/S-IG disappeared. Thus, compared with PID, an insulin clamp with SID underestimates the contribution of liver in response to insulin to whole body glucose flux.
insulin clamp method; portal-systemic insulin gradient; liver; muscle IN METABOLIC SYNDROMES, DISTURBED GLUCOSE HOMEOSTASIS is associated with altered sensitivity (responsiveness) of various organs to insulin and altered secretion of this hormone from pancreatic ␤-cells (18) . Insulin regulates blood glucose levels by stimulating glucose disposal in insulin-sensitive tissues/ organs while suppressing glucose production in liver and kidney (18) . Critical for understanding the underlying pathology of disturbed glucose homeostasis associated with metabolic syndrome is an accurate comparison of glucose metabolism in glucose disposing and producing organs/tissues under pathological insulinemia associated with the disease to that of insulinemia found in normal subjects, along with a comparison of insulin sensitivity in tissue/organs contributing to glucose disposal and production. The insulin clamp technique has been widely used for this purpose in humans (40, 61, 94) as well as animals (1, 19, 24, 42, 61, 79) . Basically, this technique allows one to maintain plasma insulin at the desired level by infusing this hormone intravenously while maintaining plasma glucose levels by intravenously infusing glucose, if necessary, to block the glucose-insulin feedback loop. With the use of radioisotopes, such as [ 3 H]glucose, in conjunction with an insulin clamp, endogenous glucose production (EGP) and glucose disappearance (R d ) can be measured, allowing the differentiation between hepatic and peripheral insulin sensitivity. Unfortunately, this potentially powerful technique suffers from no standardized method. Multiple variations of the insulin clamp technique exist among research groups, especially in terms of insulin delivery routes (systemic vs. portal delivery) as well as management of endogenous insulin/glucagon secretion (either with or without endogenous insulin and glucagon secretion inhibited by somatostatin).
Physiologically, insulin and glucagon secreted from the pancreas flow directly into the hepatic portal vein and pass through the liver before reaching the systemic circulation. Circulating insulin (11, 84) and glucagon (17, 37) have, as a consequence of their fundamental role in the maintenance of glycemia (74) , by necessity a short half-life [insulin: 4 -6 min in humans (20, 57) , 3-10 min in rats (2, 38) , and ϳ10 min in mice (16) ; glucagon: ϳ7 min in humans (70) and ϳ2 min in rats (3)], allowing for small changes in their plasma concentrations to rapidly signal a response to either a hyperglycemic or hypoglycemic challenge (23) . The liver is the primary site of clearance of insulin from plasma. It has been reported in both human and large animal models that the proportion of portal insulin cleared by the liver during first-pass transit is 40 -80% in humans (21, 63, 69, 93 ) and 50 -80% in dogs (15, 30, 36, 39, 62, 82) . Such high insulin clearance by liver creates a large positive concentration gradient of this hormone between portal and systemic circulation [P/S-IG: ϳ2.2 in humans (55) , ϳ1.9 in pigs (48) , and 1.9 -3.0 in dogs (25, 35, 60) ]. As a consequence, with endogenous insulin secretion, the liver is always exposed to a higher concentration of insulin compared with other organs/tissues. When an insulin clamp is performed with systemic insulin delivery (SID), the P/S-IG is lost (35) . The P/S-IG can be maintained at its physiological level during an insulin clamp when portal insulin delivery (PID) is used (80, 90) . By failing to maintain the physiologically relevant P/S-IG when an insulin clamp is performed with SID, differences in outcome measurements may result from the loss of P/S-IG and not a metabolic disease-associated disturbance in glucose ho-meostasis. In patients with type 1 diabetes, blood concentration of gluconeogenic precursors and glucose recycling were lower, and glucose infusion rates to maintain euglycemia were higher after intravenous treatment compared with intraperitoneal treatment (64) . In normal dogs, the measured rates of net hepatic glucose uptake during an insulin clamp were lower with SID compared with PID (77) . In streptozotocin-induced diabetic miniature pigs, the measured hepatic glucose output was higher with SID than with PID (12) . These studies suggest that a seemingly minor difference in the way insulin is delivered may complicate interpretation of results and subsequent conclusions.
Small animals such as mice and rats are most widely used in models of human metabolic disease and are frequently subjected to insulin clamp studies utilizing SID, without managing endogenous secretion of insulin and glucagon. It is known that insulin turnover rates and hepatic blood flow are markedly higher in rats [4 - (53) and ϳ20 ml·kg Ϫ1 ·min Ϫ1 (13) , respectively]. On the other hand, hepatic insulin clearance during first-pass transit has not been measured in such small animals. Therefore, the extent of P/S-IG under endogenous insulin secretion is unknown, and relevant differences in measured metabolic responses of the liver and extra-liver tissues during an insulin clamp with SID compared with the more physiological PID have not been determined for small animals.
The present study demonstrates that P/S-IG exists in rats to a similar degree with humans and large animals, that the insulin clamp with SID results in the loss of P/S-IG both with or without managing endogenous insulin secretion, and that the insulin clamp with SID underestimates the contribution of liver, relative to extra-liver organs/tissues, to whole body glucose flux, compared with the insulin clamp with PID at given insulin infusion rates and arterial insulin levels.
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RESEARCH DESIGN AND METHODS
Animals
Male Sprague-Dawley rats at 8 wk of age were purchased from Charles River Laboratories (Wilmington, MA). Rats were fed with Formulab Diet 5001 (Purina LabDiet; Purina Mils, Richmond, IN) and were given water ad libitum in an environmentally controlled room with a 12:12-h light-dark cycle. All experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the United States Department of Agriculture and the National Institutes of Health, and all protocols were approved by the Vanderbilt University Institutional Animal Care and Use Committee.
Experimental Design
Surgery for implanting catheters was performed 2 wk before each experiment as previously described (79) . Rats were anesthetized with isoflurane. The right external jugular vein and the left common carotid artery were cannulated with sterile silicone catheters (0.51 mm ID/ 0.94 mm OD). After a midline laparotomy from the xyphoid process to the pubic bone, silicone catheters (0.51 mm ID/0.94 mm OD) were placed in the hepatic portal vein and the ileal vein, respectively. The tips of portal and ileal vein catheters were placed close to the diverging point of the portal vein immediately before reaching the liver and at the mesenteric vein, respectively. The free ends of these catheters were passed subcutaneously to the back of the neck where they were fixed. Catheters were occluded with metal plugs following a flush of heparinized saline solution (200 U heparin/ml).
Studies were performed on 12-to 14-wk-old rats. Rats were fasted from 6:00 A.M. on the study day. Each clamp study consisted of a 90-min tracer equilibration period [Ϫ150 min (10:30 A.M.) to Ϫ60 min (12:00 P.M.)], a 60-min basal period [Ϫ60 min (12:00 P.M.) to 0 min (1:00 P.M.)], and a 180-min test period [0 min (1:00 P.M.) to 180 min (4:00 P.M.)]. At Ϫ150 min, [3- 3 H]glucose was given at 20 Ci in a bolus through the jugular vein catheter followed by continuous infusion at 0.2 Ci/min.
Evaluation of effect of somatostatin on plasma insulin and glucagon concentration. During the test period, somatostatin was infused through the jugular vein catheter at 6 g·kg Ϫ1 ·min Ϫ1 in 6-h-fasted conscious rats to evaluate its effect on plasma insulin and glucagon concentration in the artery and portal vein.
Insulin clamp with PID or SID while inhibiting endogenous insulin and glucagon secretion and under euglycemic-and hyperglycemiceuglucagonemic conditions. During the test period, somatostatin was infused through the jugular vein catheter at 6 g·kg Ϫ1 ·min Ϫ1 to inhibit endogenous insulin and glucagon secretion. Human recombinant glucagon (GlucaGen; Novo Nordisk, Bagsvaerd, Denmark) was infused in the hepatic portal circulation through the ileal vein catheter at 1.6 ng·kg Ϫ1 ·min Ϫ1 to maintain its basal levels. Human recombinant insulin (Novolin; Novo Nordisk) was infused at 1, 2, or 5 mU·kg
Ϫ1
·min
Ϫ1 into the hepatic portal circulation through the ileal vein catheter or into the systemic circulation through the jugular vein catheter. Plasma glucose levels were kept at basal or ϳ15 mM by infusing 50% dextrose solution (D50; Hospira, Lake Forest, IL) into the systemic circulation through the jugular vein catheter at a variable rate, if necessary.
Hyperinsulinemic-euglycemic clamp by systemic insulin delivery without managing endogenous insulin and glucagon secretion. During the test period, human recombinant insulin (Novolin; Novo Nordisk) was infused into the systemic circulation through the jugular vein catheter at 2 or 5 mU·kg Ϫ1 ·min Ϫ1 . Plasma glucose levels were maintained at basal by infusing D50 into the systemic circulation through the jugular vein catheter at variable rates, if necessary.
Hyperinsulinemic-hyperglycemic clamp by systemic insulin delivery without managing endogenous insulin and glucagon secretion. During the test period, D50 was infused at variable rates into the systemic circulation through the jugular vein catheter to maintain plasma glucose levels at ϳ15 mM. Human recombinant insulin (5 mU·kg Ϫ1 ·min Ϫ1 ) or vehicle was infused into the systemic circulation during the hyperglycemic clamp.
Blood and tissue collection. To measure [3- 3 H]glucose specific activity in plasma, blood (100 l) was collected from the artery though the arterial catheters once every 30 min during the basal and test period. To measure insulin, glucagon, and metabolite concentrations in the artery and portal vein in addition to [3- 3 H]glucose specific activity in plasma, blood (400 l) was collected simultaneously through the arterial and hepatic portal vein catheters at 0 min during the basal period and at 60, 120, and 180 min during the clamp period. Arterial blood glucose levels were monitored using the Accu-Check glucometer (Roche Diagnostics, Indianapolis, IN) one time every 10 min during the clamp period. At each sampling time, erythrocytes were resuspended in saline and given back to the test animal during the study. At the end of each study, rats were anesthetized with the infusion of pentobarbital sodium (50 mg/kg) through the arterial catheter, and a laparotomy was performed immediately. The left lobe of liver and skeletal muscle (vastus lateralis) were rapidly removed and frozen using Wollenberg tongs precooled in liquid nitrogen.
Analytical Methods
The concentrations of total insulin and human insulin in plasma were determined using a sensitive rat insulin radioimmunoassay kit (Millipore, Billerica, MA) and an ultrasensitive human insulin radioimmunoassay kit (Millipore), respectively. Guinea pig anti-rat insulin serum used in the sensitive rat insulin radioimmunoassay kit has 100% cross-reactivity with human insulin. Guinea pig anti-human insulin serum used in the ultrasensitive human insulin radioimmunoassay kit has ϳ7% cross-reactivity with rat insulin. The concentrations of glucagon in plasma were determined using a glucagon radioimmunoassay kit (Millipore). The concentrations of C-peptide in plasma were measured using a rat C-peptide ELISA kit (ALPCO, Salem, NH).
The glycogen in liver and skeletal muscle, plasma nonesterified free fatty acids (FFAs), blood lactate and alanine, and the specific activity of [3- 3 H]glucose were determined as previously described (89) .
Calculations [3-
3 H]glucose was used to determine the rates of unlabeled glucose appearance (Ra) and disappearance (Rd) as calculated using Steele's equation (89) , which is based on a one-pool model and on the initial assumption of instant mixing of glucose in its entire space. Endogenous glucose production rate was determined as the difference between R a and exogenous glucose infusion rates. To estimate the amount of glucose incorporated into glycogen via the direct pathway, 3-3 H incorporated into glycogen was divided by the plasma glucose 3-3 H specific activity (89) .
Statistical Analyses
Data are expressed as means Ϯ SE. For the time-course data, the significance of differences between groups was analyzed using two-way repeated-measures ANOVA. Otherwise, significant differences between groups were evaluated using unpaired Student's t-test. Probabilities Ͻ5% (P Ͻ 0.05) were considered to be statistically significant.
RESULTS
P/S-IG Before and During an Insulin Clamp with PID and SID While Inhibiting Endogenous Insulin and Glucagon Secretion
At basal, plasma insulin concentrations (ng/ml) in the portal vein (1.82 Ϯ 0.07, n ϭ 64) were approximately two times (portal-to-arterial ratio 2.07 Ϯ 0.05, n ϭ 64) those in the artery (0.89 Ϯ 0.04, n ϭ 64) (Tables 1 and 2 ). Glucagon concentrations (pg/ml) in the portal vein (61.3 Ϯ 2.7, n ϭ 64) were ϳ40% higher (portal-to-arterial ratio 1.36 Ϯ 0.07, n ϭ 64) than those in the artery (45.1 Ϯ 2.3, n ϭ 64) (Tables  1 and 2 ). An infusion of somatostatin reduced plasma insulin and glucagon by 95% (Fig. 1A) and 60% (Fig. 1C) , respectively, and extinguished a positive concentration gradient of these hormones between portal and systemic circulation ( Fig. 1, B and D) .
During an euglycemic insulin clamp with PID at 1 mU·kg Ϫ1 ·min Ϫ1 (Table 1 and Fig. 2A ), plasma insulin concentrations in the artery and portal vein decreased by 45 and 30%, respectively, from their basal values. When PID rates were increased to 2 and 5 mU·kg Ϫ1 ·min Ϫ1 , plasma insulin levels in both the artery and portal vein rose linearly and proportionally with increased rates of insulin infusion ( Fig. 2A) . P/S-IG was not altered by an increase in insulin infusion rate and remained at basal levels ( Fig. 2B) . During a euglycemic insulin clamp with SID at 1 mU·kg Ϫ1 ·min
Ϫ1
, from its basal levels, plasma insulin concentrations rose by ϳ20% in the artery, but fell by ϳ60% in the portal vein (Table 1) . By increasing SID rate to 2 mU·kg
, plasma insulin concentrations doubled in the artery but remained around basal levels in the portal vein ( Fig. 2A) . With a SID rate at 5 mU·kg Ϫ1 ·min Ϫ1 , plasma insulin concentration increased from its basal level 4.8 times in the artery but only 2.3 times in the portal vein. Compared with PID, arterial insulin concentrations with SID were ϳ50 -100% higher while portal insulin concentrations were about half at all insulin infusion rates ( Fig. 2A ). There were no changes in P/S-IG with any insulin infusion rates (Fig. 2B ).
In combination with hyperglycemia (Table 2 and Fig. 3 ), the differences in plasma insulin concentration in the portal vein and the artery (Fig. 3A) , as well as P/S-IG (Fig. 3B) , between PID and SID were similar to those measured under Values are means Ϯ SE of 6 studies for each group. P/A, portal vein-to-arterial ratio of plasma insulin concentration; FFAs, free fatty acids; A, artery; P, portal vein; PID, portal insulin delivery; SID, systemic insulin delivery. *Significant difference from the corresponding values of PID group (P Ͻ 0.05). †Significant change from basal value in the identical group (P Ͻ 0.05). euglycemia. As shown in Fig. 4 , for a wide range of plasma insulin levels, there was a linear correlation in plasma insulin levels between the portal vein and the artery under basal conditions and during insulin clamps with both PID and SID. The P/S-IG ratio was 0.87 with SID, whereas this ratio was 2.2 with PID. The latter was very close to the basal P/S-IG ratio of 2.07 determined under basal endogenous insulin secretion. In addition, endogenous insulin secretion was increased under hyperglycemic conditions (Fig. 7B ), yielding a P/S-IG ratio of 2.06 Ϯ 0.29 [8.28 Ϯ 1.35 ng/ml in the artery and 17.08 Ϯ 5.29 in portal vein, (n ϭ 6)], suggesting that P/S-IG remains constant with changes in endogenous insulin secretion.
Comparison of Glucose Flux During Insulin Clamps With Either PID or SID Under Euglycemic and Hyperglycemic Conditions
Insulin action on carbohydrate metabolism is to increase glucose disposal via stimulation of glucose uptake and its subsequent intracellular oxidative and nonoxidative metabolism in insulin-sensitive tissues/organs, as well as via inhibition of hepatic glucose production. In animals that had insulin clamps with either PID or SID while inhibiting insulin and glucagon secretion under euglycemic conditions (Table 1 and Fig. 2 ), glucose infusion rates (GIR) required to maintain basal plasma glucose levels, R d , and rates of glucose incorporation into glycogen (GSR) in liver and muscle increased linearly, whereas EGP decreased linearly, with increasing insulin infusion rates (Fig. 2 ). GIRs were similar for both insulin delivery routes with an insulin infusion rate at 2 and 5 mU·kg Ϫ1 ·min Ϫ1 (Table 3 and Fig.  2C ). However, with SID, compared with PID, R d , EGP, and GSR in skeletal muscle were significantly higher at all insulin infusion rates (Table 3 and Fig. 2, D, E, and H) , and glycogen content at the end of the test period was significantly higher at the insulin infusion rate of 5 mU·kg Ϫ1 ·min Ϫ1 (Fig.  2F) . In contrast, glycogen content at the end of the test period and GSR in liver tended to be lower with insulin infusion rates of 2 (P Ͻ 0.15 and P Ͻ 0.08, respectively) and 5 (P Ͻ 0.20 and P Ͻ 0.22, respectively) mU·kg Ϫ1 ·min Ϫ1 (Table 3 and Fig. 2, G and I ). There were no significant differences in blood lactate and alanine levels between PID and SID (Table 1) , whereas plasma FFAs levels tended to be lower with SID (Table 1 ). In animals that had the same type of insulin clamps but under hyperglycemic conditions (Table 2 and Fig. 3 ), the differences in measured parameters between PID and SID were more prominent compared with euglycemic conditions (Table 1 and Fig. 2) . When R d , GSR in muscle, EGP, and GSR in liver are compared with arterial insulin concentrations for PID and SID (Fig. 5), R d (Fig. 5A) and GSR (Fig. 5C ) in muscle were relatively similar, but EGP (Fig. 5E ) and GSR (Fig. 5G ) in liver were markedly different. Comparing these parameters against portal insulin concentrations, EGP (Fig. 5F ) and GSR (Fig. 5H ) in liver were similar, but R d (Fig. 5B) and GSR (Fig. 5D ) in muscle were markedly different. These data support the notion that insulin action on extra-hepatic tissues/organs depends on the arterial insulin concentration, whereas insulin action on the liver depends on the portal insulin concentration. , and portal-to-arterial ratio of plasma insulin concentration (B), rates of glucose infusion (C), glucose disappearance (D), endogenous glucose production (E), glycogen content in muscle (F) and liver (G), and glycogen synthesis from plasma glucose via the direct pathway in muscle (H) and liver (I) in relation to insulin infusion rates during plasma insulin clamps with portal (PID) and systemic (SID) insulin delivery under euglycemic conditions in 6-h-fasted conscious rats. Data are means Ϯ SE of the average of the values at 3 time points (60, 120, and 180 min) for insulin and 5 time points (60, 90, 120, 150, and 180 min) for glucose flux during the clamp period and mean Ϯ SE for the values at the end of the test period for glycogen content for 6 experiments. *Significantly different from the corresponding values of the portal insulin infusion group (P Ͻ 0.05).
Effect of SID on Endogenous Insulin Secretion and P/S-IG Under Euglycemia
As shown in Fig. 6 , when human recombinant insulin was infused at 2 mU·kg Ϫ1 ·min Ϫ1 systemically and plasma glucose was maintained at basal levels, total insulin levels in the artery rose to approximately two times the basal value (from 1.0 at basal to 2.3 ng/ml), but total insulin levels in the portal vein rose only 20% (from 1.8 to 2.1 ng/ml) (Fig. 6B) . Consequently, the P/S-IG was reduced from 1.9 at basal to 0.9. Human recombinant insulin comprised 100 and 80% of total insulin in the artery and portal vein, respectively (Fig. 6B) . Plasma C-peptide levels decreased by 90% within 3 h after initiating SID (Fig. 6C) , which indicated a marked decrease in endogenous insulin secretion. Plasma glucagon levels were 10 -20% higher in the portal vein compared with those in the artery, but plasma glucagon levels and the portal-arterial glucagon gradients were not significantly altered from basal by SID (Fig. 6D) .
When human recombinant insulin was infused at 5 mU·kg Ϫ1 ·min Ϫ1 systemically and plasma glucose was maintained at basal, while total insulin levels in the artery and portal vein rose to ϳ5 and 2.5 times basal levels, respectively. P/S-IG was reduced from 1.9 at basal to 0.9 with SID (Fig. 6F) . Rat insulin in plasma was completely replaced by infused human recombinant insulin (Fig. 6F) , and plasma C-peptide levels decreased by 95% within 3 h after the initiation of SID (Fig.  6G) , which indicated that endogenous insulin secretion was completely suppressed. Plasma glucagon levels dropped by 50%, and the portal-arterial glucagon gradient disappeared, which indicated a marked decrease in endogenous glucagon secretion as well (Fig. 6H) .
Effect of SID on Endogenous Insulin Secretion and P/S-IG Under Hyperglycemia
When plasma glucose levels were raised from basal values of 8 to 13 mM (Fig. 7A) without an insulin infusion, arterial and portal plasma insulin levels rose proportionally to ϳ10 times their basal values (Fig. 7B) . Plasma C-peptide levels increased seven times their basal values (Fig. 7C) , and the P/S-IG remained at 2.0 (Fig. 7B) . Plasma glucagon levels dropped by 50%, and the portal-arterial glucagon gradient of plasma glucagon was lost within 3 h of raising plasma glucose levels (Fig. 7D) .
When human recombinant insulin was infused at 5 mU·kg Ϫ1 ·min Ϫ1 systemically with a similar increase in plasma glucose (Fig. 7E) , total insulin levels doubled in the artery and increased by 50% in the portal vein (Fig. 7F ) compared with insulin levels observed following glucose infusion alone (Fig.  7B) . Infused human recombinant insulin comprised 50 and 40% of total insulin in the artery and portal vein, respectively. The absolute levels of human recombinant insulin in the artery and portal vein were approximately double their value found under euglycemic conditions despite the same rate of insulin infusion. Plasma C-peptide concentrations rose seven times basal (Fig. 7G) , and the absolute levels of rat insulin (Fig. 7F ) and C-peptide (Fig. 7G) in the artery and portal vein were similar to those under hyperglycemia without SID (Fig. 7, B and C). The P/S-IG was lower than that with hyperglycemia without SID (Fig. 7B) . Plasma glucagon concentration in the artery and portal vein decreased by ϳ50%, and the portalarterial glucagon gradient disappeared (Fig. 7D) .
DISCUSSION
In the present study, as found in human and large animals, normal rats, a small animal model, have a comparable positive P/S-IG over a wide range of plasma insulin concentrations under conditions of endogenous insulin secretion and during an insulin clamp with PID. We demonstrated that an insulin clamp with SID leads to complete extinguishment of P/S-IG and underestimates the contribution of liver, relative to extrahepatic tissues, to whole body glucose flux in response to insulin. (53) . Yet, the P/S-IG value in rats (2.07) under endogenous insulin secretion is similar to those of humans (2.2) (55), pigs (1.9) (48), and dogs (1.9 -3.0) (25, 35, 60) , suggesting that rats have higher hepatic insulin extraction rates that are proportional to their higher insulin secretion rates. Consequently, rats have similar hepatic clearance of insulin from the portal vein with its first pass through the liver compared with dogs (50 -80%) and humans (40 -80%) (30, 36, 39) .
P/S-IG Extinguishes With SID
During an insulin clamp with SID, compared with PID at equivalent insulin infusion rates, arterial insulin concentrations are ϳ30 to 100% higher, whereas portal insulin concentrations are about one-half at all insulin infusion rates, which indicates that extra-hepatic tissues are exposed to higher insulin concentrations, while insulin delivered to the liver via the portal vein is reduced. In contrast to extra-hepatic tissues, hepatocytes are exposed to hormones and nutrients in the sinusoid that receives a dual blood supply from the hepatic artery and portal vein (92) . Consequently, the concentration of insulin in a liver sinusoid is determined by the relative blood flow between the hepatic artery and portal vein in addition to insulin levels in both vessels. The fraction of hepatic arterial blood flow relative to total hepatic blood flow has been reported to be ϳ20% in anesthetized rats (49, 56) and ϳ6% in nonanesthetized rats (14, 76) . Even if the dilution of portal blood by arterial blood in the liver sinusoid is taken into consideration, sinusoidal insulin levels would reflect that of the portal vein and would be markedly lower with SID. Thereby, unlike with PID, even when arterial and portal blood flows are considered, SID eliminates P/S-IG and lowers the insulin exposure of liver relative to extra-hepatic tissues.
Reduced Contribution of Liver to Whole Body Glucose Flux Relative to Extra-Hepatic Tissues During an Insulin Clamp with SID Compared With PID
The absence of P/S-IG, a reflection of insulin distribution between portal and systemic circulation during an insulin clamp with SID, seems to set the relative contribution of liver and extra-hepatic tissues to whole body glucose flux in response to insulin apart from that seen under endogenous insulin secretion or during an insulin clamp with PID. Insulin works to reduce blood glucose levels by increasing glucose disposal and suppressing EGP. Insulin-induced suppression of EGP is due to decreased net hepatic glucose production that results from both decrease in glucose production and increased glucose uptake for its storage as glycogen. During an insulin clamp with SID, compared with PID at equal insulin infusion rates, EGP was higher, and hepatic glycogen synthetic rates were lower. On the other hand, the GIRs needed to maintain euglycemia, which has been suggested to be a reflection of insulin action (1), were similar in an insulin infusion rate at 2 and 5 mU·kg Ϫ1 ·min Ϫ1 . The concentrations of glucagon and glucose were clamped at similar levels during insulin clamps with both SID and PID. The concentrations of gluconeogenic precursors, lactate and alanine, in the circulation were also not significantly different between the insulin delivery routes. Likewise, peripheral glucose flux plotted against arterial insulin levels and hepatic glucose flux against portal insulin levels were similar between SID and PID. Therefore, a lower response of hepatic glucose flux to an insulin clamp with SID likely results from a lower sinusoidal concentration of insulin.
Endogenous Insulin Secretion is Completely Suppressed During Hyperinsulinemic-Euglycemic Clamps With SID Even Without Managing Endogenous Secretion of Pancreatic Hormones With Somatostatin
In small animals, mice and rats, euglycemic-hyperinsulinemic clamps have been frequently performed with SID and without inhibiting endogenous insulin secretion by somatostatin treatment. One expects endogenous insulin secretion to be sustained and thus the P/S-IG to be maintained during the clamp. However, this may not be the case if insulin either directly or indirectly regulates its own secretion. The feedback effect of insulin on its secretion from ␤-cells has been a matter of debate with both conceptual disagreement and contradictory experimental evidence (51) . One argument, based on in vitro evidence, proposes insulin can mediate an immediate positive feedback type of regulation of its own secretion by increasing intracellular Ca 2ϩ levels within ␤-cells that stimulates exocytosis. In contrast, a different argument supports an immediate negative feedback mechanism based on the observation that insulin opens ATP-dependent K ϩ (K ATP ) channels that hyper- polarize the plasma membrane and decrease exocytosis. In the present in vivo study, SID at 2 mU (ϳ12 pmol)·kg Ϫ1 ·min Ϫ1 , which raised the arterial insulin concentration only two times that of basal, inhibited endogenous insulin secretion almost completely, as evidenced by complete replacement of rat insulin by infused human recombinant insulin and complete absence of C-peptide in plasma. As a result, P/S-IG was completely extinguished. The insulin concentrations measured in both the artery and portal vein and P/S-IG during an insulin clamp with SID without managing endogenous insulin secretion are quite similar to those seen during an insulin clamp with SID at the same rate of insulin infusion while inhibiting endogenous insulin secretion by somatostatin treatment. With regard to the conceptual disagreement about insulin feedback regulation, a proposed explanation is that the insulin concentration in the islet pericapillary interstitial space would be much higher than its arterial concentration, since insulin is secreted into the islet pericapillary interstitial space and then diffuses into the capillary bloodstream though the capillary wall. Thereby, ␤-cells are constantly exposed to the concentration of insulin in the islet pericapillary interstitial space, and, consequently, insulin-induced negative-feedback signal must be desensitized or saturated (51) . It has been reported that insulin is coordinately secreted as secretory bursts into the hepatic portal vein (72, 85) and that the burst of insulin secretions is regulated by the magnitude of insulin pulses (71, 73) . Increased insulin secretion from ␤-cells raises the insulin concentration around ␤-cells, inhibiting insulin secretion in an autocrine manner. Consequently, as local insulin levels fall near ␤-cells, this decrease in insulin concentration leads to increases in insulin secretion by removing its negative feedback signal (51) . The bottom level of local insulin concentration might be raised by exogenous infusion of insulin and kept at a level where the negative feedback signal might be maintained. This might explain the conceptual contradiction (51) . Additionally, it is also possible that the inhibition of insulin secretion by systemic insulin infusion is secondary to a change in a systemic factor, not due to its direct effect on ␤-cells. No matter the mechanism, our results clearly indicate that a hyperinsulinemic-euglycemic clamp with SID is unable to sustain the P/S-IG even if the clamp is performed without managing endogenous insulin secretion in rats.
SID at an insulin infusion rate of 5 mU·kg Ϫ1 ·min Ϫ1 , which completely inhibited endogenous insulin secretion under euglycemia, did not inhibit endogenous insulin secretion under hyperglycemic conditions. It has been reported that a rise in plasma glucose concentration stimulates insulin secretion from pancreatic ␤-cells via closure of K ATP channels by increasing the intracellular energy charge (ATP-to-ADP ratio), whereas insulin inhibits its own secretion by opening K ATP channels via a phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase B (Akt)-dependent signaling pathway (50) . Therefore, it is implied that plasma glucose and insulin regulate insulin secretion in a competitive manner at the level of K ATP channels to either stimulate or inhibit insulin secretion, respectively. 
Endogenous Glucagon Secretion is Reduced During Hyperinsulinemic-Euglycemic Clamps With SID Even Without Managing Endogenous Secretion of Pancreatic Hormones With Somatostatin Treatment
A portal-arterial gradient of plasma glucagon levels results from a high first-pass extraction of glucagon by the liver (36) so that peripheral glucagon concentrations are substantially lower than portal vein levels, as reported for humans (P/A: 1.5) (7) and in dogs (P/A: 1.5ϳ1.8) (35, 36, 90) . In the present study, measured plasma glucagon concentrations under basal and clamp conditions in the artery (45.1 Ϯ 2.3 and 39.9 Ϯ 1.6 pg/ml, respectively, n ϭ 55) and the portal vein (61.3 Ϯ 2.7 and 59.1 Ϯ 2.4 pg/ml, respectively, n ϭ 55) showed a portal-arterial glucagon gradient ratio of 1.36 Ϯ 0.07 and 1.48 Ϯ 0.05, respectively. It is worth noting that the liver is being exposed to a much higher concentration of glucagon than that measured in the artery under physiological glucagon delivery in small animals, as seen in large animals.
Insulin as well as glucose plays a role in regulation of plasma glucagon levels (29) . Insulin inhibits glucagon secretion from the pancreatic ␣-cells by opening K ATP channels via a PI 3-kinase/Akt-dependent signaling pathway, which insulin utilizes to inhibit its own secretion from pancreatic ␤-cells (4, 41) . During an insulin clamp with SID without managing endogenous secretion of pancreatic hormones, glucagon levels were not reduced by a doubling of plasma insulin levels, even though this level of insulin completely inhibited endogenous insulin secretion. However, glucagon secretion was inhibited with a fivefold ele- vation in plasma insulin levels, as evidenced by a reduction in plasma glucagon levels by ϳ50%.
Absolute plasma concentrations of glucagon were never reduced by Ͼ60% by hyperinsulinemia, nor by the combination of hyperinsulinemia and hyperglycemia. Yet the reduction was sufficient to eliminate the portal-arterial gradient of plasma glucagon, suggesting decreased extraction by the liver or complete suppression of biologically active endogenous glucagon secretion. We were not able to identify the etiology of the remaining 40% of immunoreactive glucagon found in the plasma of these animals. Nevertheless, endogenous glucagon secretion is likely completely inhibited by at least 5 ng/ml of arterial insulin; thus, the altered hepatic glucose flux during the hyperinsulinemic clamp without managing endogenous pancreatic hormones might result from not only increased insulin but also decreased glucagon.
What We Learned From This Study
In rats (19, 28, 31, 44, 46, 65, 83) , hyperinsulinemiceuglycemic clamps have been widely performed with SID at a range of insulin infusion rates from 1.5 to 5 mU·kg Ϫ1 ·min Ϫ1 , which raise plasma insulin in the systemic circulation ϳ1.5-6 times that of basal values in animals fasted for 5-6 h. The present study illustrates that in rats, using a similar range of insulin infusion rates and elevation of arterial insulin levels, the insulin clamp with SID inadequately estimates the contribution of liver, relative to extra-hepatic tissues, to whole body glucose flux in response to insulin. In addition, it has been suggested that insulin inhibits EGP or stimulates hepatic glucose uptake via its action in the hypothalamus (52) as well as by reducing plasma FFA levels by inhibiting lipolysis in adipose tissue (6) . Because these effects are dependent on arterial insulin levels, it is likely that the fraction of the indirect regulation by insulin of hepatic metabolism during the insulin clamp with SID is larger compared with PID. Most importantly, when arterial plasma insulin levels are clamped a mere twofold above basal levels by SID, concentrations of insulin in the portal vein are reduced below their basal values, causing the liver to experience insulin deficiency while extra-hepatic tissues are exposed to hyperinsulinemia.
Mice are also regularly used in studies of metabolic regulation using an insulin clamp technique in combination with gene engineering techniques. These insulin clamps are usually performed with SID without managing endogenous secretion of pancreatic hormones (1, 42) . Compared with insulin clamps in rats, insulin clamps in mice have been performed with a much larger range of insulin infusion rates (from 0.8 to 20 mU·kg Ϫ1 ·min Ϫ1 ), which raised plasma insulin concentrations in the systemic circulation by ϳ0.8 -20 times that of basal values in animals fasted for 5-10 h (1, 5, 8, 33, 42, 54, 66, 67, 95) . Preliminary studies performed by us in anesthetized mice showed that P/S-IG [1.9 Ϯ 0.3, n ϭ 5 (unpublished result)] also exists in these small animals. It was reported that the insulin infusion at 0.8 mU·kg Ϫ1 ·min Ϫ1 decreased plasma insulin in the systemic circulation (1), implying that an insulin infusion could reduce endogenous insulin secretion in mice.
P/S-IG depends largely on hepatic extraction rate of insulin during the first pass against hepatic load of this hormone. The primary cellular mechanism for hepatic uptake and degradation of insulin is a receptor-mediated process, and insulin-degrading enzyme is a rate-limiting enzyme in the insulin degradation process (91) . Humans with obesity and glucose intolerance (9, 68, 75) , as well as animals fed with high-fat or cafeteria (10, 43, 86) diet, have decreased hepatic insulin extraction that associates with reduced insulin sensitivity and decreased activity of insulin-degrading enzyme (10) . Elevated circulating and hepatic free fatty acid levels impair insulin binding and degradation in dogs (96) and in isolated rat hepatocytes (32, 87) . It is likely, therefore, that P/S-IG decreases under pathological and nutritional conditions accompanied by hepatic insulin resistance, although the range of reduction of P/S-IG is difficult to predict without direct measurement of P/S-IG. In addition to increased insulin secretion, reduced hepatic insulin extraction contributes to hyperinsulinemia seen with obesity and high-fat-diet-induced insulin resistance (22, 75) . This altered distribution of insulin between portal and systemic circulation may contribute to altered whole body glucose flux in subjects with hepatic insulin resistance, such as subjects with obesity, diabetes, or high-fat-diet feeding. The contribution of this altered distribution of insulin between portal and systemic circulation, reflected by a change in P/S-IG, on glucose metabolism in liver and extra-hepatic tissues, as well as whole body glucose flux, under pathological conditions can be assessed using an insulin clamp with PID, but not SID.
Because the surgical procedure required for portal vein access is technically challenging, especially for mice and not practical for humans, SID will most likely remain the most popular insulin delivery route for insulin clamp. As long as one considers its limitations, an insulin clamp with SID can be used to evaluate insulin sensitivity and metabolic response to insulin in extra-hepatic tissues, because these tissues are exposed to arterial insulin, which can be measured. On the other hand, even though the sinusoidal insulin concentration is predictable from arterial insulin concentration, to evaluate hepatic insulin sensitivity and metabolic response to insulin with SID, one has to take in consideration that the fraction of the indirect regulation by insulin of hepatic metabolism during the insulin clamp with SID is larger compared with PID and that reduced glucagon signaling may contribute to the response, if compensatory glucagon is not infused. Furthermore, an insulin clamp with SID may not provide true physiological reflection of the relative role of the direct and indirect effect of insulin on the liver with respect to regulation of hepatic metabolism nor to the relative contribution of liver with respect to extra-liver tissues to whole body glucose flux during physiological and pathological insulinemia.
Insulin is secreted from pancreatic ␤-cells in coordinate secretory bursts into the hepatic portal vein (72, 85) . The vascular anatomy of hepatic sinusoids permits direct exposure of hepatocytes to the oscillating wave front of insulin concentration (85). Matveyenko et al. reported that the pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling in dogs (58) . Impaired pulsatile insulin delivery has been considered to play a role in impaired hepatic metabolism in type 1 and type 2 diabetes (34, 45, 47) . In insulin clamps previously performed with PID (14, 26, 27, 78, 79, 88, 89) and in the present study, insulin concentrations in the sinusoid might not oscillate, given the constant infusion of insulin. Therefore, insulin clamps with PID may still underestimate the role of liver metabolism in whole body glucose flux in response to insulin. Despite this limitation, insulin clamps performed with PID, compared with SID, maintain a more physiological environment, which allows for a more precise understanding of the balance between liver and extra-hepatic tissues in the metabolic response to insulin in both healthy and diseased models.
